Since the 1800s, scientists have pushed governments to overhaul water supply systems for cleaner, safer water to stop the outbreak of waterborne pathogens. Now, researchers are calling for a similar “paradigm shift” in indoor ventilation systems to combat Covid-19 and other airborne pathogens.
GlaxoSmithKline and Germany-based CureVac forged a strategic collaboration worth nearly $1 billion to develop up to five messenger RNA-based vaccines and monoclonal antibodies targeting infectious disease pathogens.
The chief executive of AstraZeneca, which is developing a leading coronavirus vaccine with Oxford University, said it is too early to deliberately expose trial participants to the pathogen, but it may become an option if ongoing tests hit a snag.
As some U.S. states look to start reopening their coronavirus-battered economies amid protests from supporters of President Donald Trump anxious to get back to work, hardest hit New York state began mandating the wearing of masks or face coverings in public to contain the pathogen’s spread.
The U.S. Department of Health and Human Services is partnering with Regeneron Pharmaceuticals Inc. to develop a treatment for the coronavirus, making the drugmaker the latest to join the race to develop a therapy.
Shionogi & Co. Ltd. announced results from APEKS-NP, an international, double-blind, randomized Phase III clinical trial evaluating the efficacy and safety of the investigational antibiotic cefiderocol in patients with nosocomial pneumonia (NP).
Researchers with Cortexyme published research in the journal Science Advances describing the role of Porphyromonas gingivalis, a bacteria that causes gingivitis, to Alzheimer’s disease.
Drugmakers’ response to the threat posed by “superbugs” remains patchy even after years of warnings, according to the first analysis of individual companies’ efforts to tackle the antibiotic resistance crisis.
AvidBiotics is splitting into two separate companies. AvidBiotics developed two separate but similar technology platforms, which will be the foundation for the two companies. Both companies’ technology utilize proteins that attack specific cells. One platform focuses on cancer cells while the other focuses on bacteria.
New antibiotics need to be developed urgently to combat 12 bacteria families, “priority pathogens” that are the greatest threats to human health, WHO says.